pomotrelvir   Click here for help

GtoPdb Ligand ID: 12958

Synonyms: PBI 0451 | PBI0451
Compound class: Synthetic organic
Comment: Pomotrelvir (PBI-0451; Pardes Biosciences) is an orally administered SARS-CoV-2 Mpro competitive inhibitor [1]. It exhibits antiviral activity against a range of known SARS-CoV-2 variants in vitro.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 4
Rotatable bonds 10
Topological polar surface area 123.12
Molecular weight 455.94
XLogP 1.66
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES C1=CC2=C(C(=C1)Cl)NC(=C2)C(=O)N[C@@H](CC3CC3)C(=O)N[C@@H](C[C@@H]4CCCNC4=O)C#N
Isomeric SMILES C1C[C@H](C(=O)NC1)C[C@@H](C#N)NC(=O)[C@H](CC2CC2)NC(=O)C3=CC4=C(N3)C(=CC=C4)Cl
InChI InChI=1S/C23H26ClN5O3/c24-17-5-1-3-14-11-19(28-20(14)17)23(32)29-18(9-13-6-7-13)22(31)27-16(12-25)10-15-4-2-8-26-21(15)30/h1,3,5,11,13,15-16,18,28H,2,4,6-10H2,(H,26,30)(H,27,31)(H,29,32)/t15-,16-,18-/m0/s1
No information available.
Summary of Clinical Use Click here for help
Pomotrelvir (PBI-0451) has advanced to clinical evaluation as a treatment for symptomatic COVID-19 patients who do not require hospitalisation.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05543707 PBI-0451 (Pomotrelvir) Phase 2 Study in Nonhospitalized Symptomatic Adults With COVID-19 Phase 2 Interventional Pardes Biosciences, Inc.